New York, Feb 5, 2026, 14:24 EST — Regular session underway.
Boston Scientific shares climbed roughly 3.3% on Thursday, recovering some losses after a steep drop the previous day shook investors concerned about the medical device maker’s 2026 outlook. The stock traded at $77.97 in afternoon trading.
The bounce is significant because Boston Scientific has long been seen as a reliable player in heart devices, and Wednesday’s surge reshaped expectations for what “steady” means by 2026. Traders now view upcoming catalysts—segment trends, trial data, procedure volumes—as a litmus test to determine if the sell-off was an overreaction or a clear warning.
Boston Scientific’s shares plunged as much as 17% on Wednesday, marking their biggest one-day drop in over 25 years, after the company missed sales expectations in its electrophysiology unit — the segment selling devices for minimally invasive heart rhythm disorder treatments. Citi analyst Joanne Wuensch said investor concerns “were not misplaced,” despite CEO Michael Mahoney expressing he was “really pleased” with 35% organic growth in electrophysiology. Mahoney also forecast the company would outpace what he described as a roughly 15% growth market in 2026. (Reuters)
Boston Scientific reported a 15.9% jump in fourth-quarter net sales, reaching $5.286 billion. Adjusted earnings climbed to 80 cents per share, up from 70 cents the previous year. For the full year 2025, the company posted net sales of $20.074 billion and adjusted earnings of $3.06 per share, driven by 15.8% organic sales growth. (Boston Scientific)
The company projects adjusted earnings between $3.43 and $3.49 per share for 2026, alongside organic sales growth of 10% to 11%. First-quarter adjusted profit is expected to hit 78 to 80 cents per share. “Organic” growth excludes currency fluctuations and certain deal impacts, while “adjusted” results leave out specific items not considered part of the core run rate. (PR Newswire)
On its earnings call, management rejected claims that demand is cooling, saying the U.S. electrophysiology market expanded by nearly 18% to 20% this quarter. The company is still taking share in pulsed field ablation, a catheter-based method using electrical pulses to treat arrhythmias. Chief Medical Officer Ken Stein told investors the CHAMPION trial could trigger “a step change in growth” for WATCHMAN if results come back positive. He also noted the company hasn’t seen any drop in uptake related to the closure of certain trials. (The Motley Fool)
Broker sentiment on Thursday stayed cautious, avoiding outright panic. UBS lowered its price target for Boston Scientific to $120 from $140 but maintained a Buy rating, citing concerns about a “growth cliff” in U.S. electrophysiology and WATCHMAN. Still, the firm highlighted possible upside tied to the upcoming CHAMPION data. (TipRanks)
Stifel cut its price target to $110 from $125 while maintaining a Buy rating. The firm noted that investors might hold off until they see “more visible signs of stability” and a clearer catalyst before diving back in aggressively. (TipRanks)
Competition remains fierce. Boston’s Farapulse system and WATCHMAN device target rapidly expanding segments in cardiovascular care. The company has highlighted competing products from bigger players like Johnson & Johnson and Medtronic as the pulsed field ablation market evolves. (Reuters)
The downside scenario is clear: if U.S. procedure growth remains weaker than anticipated — particularly in electrophysiology and WATCHMAN — the conversation moves from a “temporary miss” to a “structural slowdown.” A poor clinical update or intensified price competition in heart rhythm devices might hold the stock down, even if headline revenue growth stays in double digits.
Traders will be tracking if Thursday’s bounce sticks through the close and if the stock steadies after a rapid two-day reset of expectations. The next major checkpoint is CHAMPION-AF data, with the trial’s primary results set to drop at ACC.26 on Saturday, March 28. (Acc)
